adenine has been researched along with Brill-Symmers Disease in 16 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The most frequent treatment-emergent adverse events (AEs) in patients with FL and DLBCL, respectively, were diarrhea (16 [59%]; 16 [47%]), fatigue (12 [44%]; 16 [47%]), nausea (9 [33%]; 12 [35%]), peripheral edema (7 [26%]; 13 [38%]), decreased appetite (8 [30%]; 11 [32%]), neutropenia (6 [22%]; 11 [32%]), and vomiting (5 [19%]; 12 [35%])." | 2.94 | Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma. ( Goy, A; Guan, S; Herrera, AF; Hill, JS; Kwei, K; Liu, EA; Mehta, A; Pagel, JM; Phillips, T; Ramchandren, R; Svoboda, J, 2020) |
| "Most patients with follicular lymphoma (FL) experience multiple relapses necessitating subsequent lines of therapy." | 2.87 | Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. ( Anderson, DM; Ansell, SM; Bartlett, NL; Costello, BA; Fehniger, TA; Gomez, F; Griffith, M; Griffith, OL; Krysiak, K; Kuruvilla, JG; LaPlant, BR; Qi, J; Ramirez, C; Reeder, CB; Siegel, BA; Thye, LS, 2018) |
| "Chemoimmunotherapy in follicular lymphoma is associated with significant toxicity." | 2.82 | Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. ( Bartlett, NL; Blum, KA; Cheson, BD; Czuczman, M; Davids, MS; Jung, SH; Leonard, JP; Levine, E; Lewis, LD; Martin, P; Park, SI; Pitcher, B; Smith, SE; Smith, SM; Ujjani, CS, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| Authors | Studies |
|---|---|
| Balasubramanian, S | 2 |
| Hodkinson, B | 1 |
| Schuster, SJ | 2 |
| Fowler, NH | 3 |
| Trotman, J | 2 |
| Hess, G | 2 |
| Cheson, BD | 3 |
| Schaffer, M | 2 |
| Sun, S | 1 |
| Deshpande, S | 2 |
| Vermeulen, J | 2 |
| Salles, G | 2 |
| Gopal, AK | 2 |
| Xu, PP | 1 |
| Shi, ZY | 1 |
| Qian, Y | 1 |
| Cheng, S | 1 |
| Zhu, Y | 1 |
| Jiang, L | 1 |
| Li, JF | 1 |
| Fang, H | 1 |
| Huang, HY | 1 |
| Yi, HM | 1 |
| Ouyang, BS | 1 |
| Wang, L | 1 |
| Zhao, WL | 1 |
| Herrera, AF | 1 |
| Goy, A | 1 |
| Mehta, A | 1 |
| Ramchandren, R | 1 |
| Pagel, JM | 1 |
| Svoboda, J | 1 |
| Guan, S | 1 |
| Hill, JS | 1 |
| Kwei, K | 1 |
| Liu, EA | 1 |
| Phillips, T | 1 |
| Nastoupil, L | 2 |
| De Vos, S | 1 |
| Knapp, M | 1 |
| Flinn, IW | 1 |
| Chen, R | 1 |
| Advani, RH | 1 |
| Bhatia, S | 1 |
| Martin, P | 3 |
| Mena, R | 1 |
| Davis, RE | 1 |
| Neelapu, SS | 1 |
| Eckert, K | 2 |
| Ping, J | 1 |
| Co, M | 1 |
| Beaupre, DM | 2 |
| Neuenburg, JK | 1 |
| Palomba, ML | 1 |
| Liu, M | 1 |
| Deng, H | 1 |
| Mu, J | 1 |
| Li, Q | 1 |
| Pu, Y | 1 |
| Jiang, Y | 1 |
| Deng, Q | 1 |
| Qian, Z | 1 |
| Zhang, L | 1 |
| Nomie, K | 1 |
| Zhang, H | 1 |
| Bell, T | 1 |
| Pham, L | 1 |
| Kadri, S | 1 |
| Segal, J | 1 |
| Li, S | 1 |
| Zhou, S | 1 |
| Santos, D | 1 |
| Richard, S | 1 |
| Sharma, S | 1 |
| Chen, W | 1 |
| Oriabure, O | 1 |
| Liu, Y | 1 |
| Huang, S | 1 |
| Guo, H | 1 |
| Chen, Z | 1 |
| Tao, W | 1 |
| Li, C | 1 |
| Wang, J | 2 |
| Fang, B | 1 |
| Li, L | 1 |
| Badillo, M | 1 |
| Ahmed, M | 1 |
| Thirumurthi, S | 1 |
| Huang, SY | 1 |
| Shao, Y | 1 |
| Lam, L | 1 |
| Yi, Q | 1 |
| Wang, YL | 1 |
| Wang, M | 2 |
| Kuo, HP | 1 |
| Ezell, SA | 1 |
| Schweighofer, KJ | 1 |
| Cheung, LWK | 1 |
| Hsieh, S | 1 |
| Apatira, M | 1 |
| Sirisawad, M | 1 |
| Hsu, SJ | 1 |
| Chen, CT | 1 |
| Versele, M | 1 |
| Chang, BY | 1 |
| Jain, P | 1 |
| Kanagal-Shamanna, R | 1 |
| San Lucas, FA | 1 |
| Romaguera, J | 1 |
| Fayad, L | 1 |
| Oki, Y | 1 |
| Westin, JR | 1 |
| Medeiros, LJ | 1 |
| Fowler, N | 1 |
| Bartlett, NL | 2 |
| Costello, BA | 1 |
| LaPlant, BR | 1 |
| Ansell, SM | 1 |
| Kuruvilla, JG | 1 |
| Reeder, CB | 1 |
| Thye, LS | 1 |
| Anderson, DM | 1 |
| Krysiak, K | 1 |
| Ramirez, C | 1 |
| Qi, J | 1 |
| Siegel, BA | 1 |
| Griffith, M | 1 |
| Griffith, OL | 1 |
| Gomez, F | 1 |
| Fehniger, TA | 1 |
| Awan, FT | 1 |
| Hou, JZ | 1 |
| Yacoub, A | 1 |
| Lill, M | 1 |
| Vitolo, U | 1 |
| Spencer, A | 1 |
| Radford, J | 1 |
| Jurczak, W | 1 |
| Morton, J | 1 |
| Caballero, D | 1 |
| Gartenberg, GJ | 1 |
| Wang, SS | 1 |
| Damle, RN | 1 |
| Lee, DH | 1 |
| Kim, GW | 1 |
| Kwon, SH | 1 |
| Bukhari, A | 1 |
| El Chaer, F | 1 |
| Koka, R | 1 |
| Singh, Z | 1 |
| Hutnick, E | 1 |
| Ruehle, K | 1 |
| Lee, ST | 1 |
| Kocoglu, MH | 1 |
| Shanholtz, C | 1 |
| Badros, A | 1 |
| Hardy, N | 1 |
| Yared, J | 1 |
| Rapoport, AP | 1 |
| Dahiya, S | 1 |
| Cameron, F | 1 |
| Sanford, M | 1 |
| Maddocks, K | 1 |
| Blum, KA | 2 |
| Ujjani, CS | 1 |
| Jung, SH | 1 |
| Pitcher, B | 1 |
| Park, SI | 1 |
| Smith, SM | 1 |
| Czuczman, M | 1 |
| Davids, MS | 1 |
| Levine, E | 1 |
| Lewis, LD | 1 |
| Smith, SE | 1 |
| Leonard, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma[NCT01779791] | Phase 2 | 110 participants (Actual) | Interventional | 2013-04-17 | Completed | ||
| A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of iR2 (Ibrutinib，Lenalidomide, Rituximab）in Untreated and Unfit Elderly Patients With Diffuse Large B-cell Lymphoma[NCT03949062] | Phase 2 | 30 participants (Actual) | Interventional | 2019-03-13 | Active, not recruiting | ||
| Phase 2 Trial of Single-Agent Ibrutinib (PCI-32765) in Relapsed or Refractory Follicular Lymphoma[NCT01849263] | Phase 2 | 41 participants (Actual) | Interventional | 2013-04-02 | Active, not recruiting | ||
| Efficacy and Safety of Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma：a Single-center, Open-label, Pragmatic Clinical Trial[NCT05020392] | Phase 3 | 24 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | ||
| A Multicenter Clinical Study of Orelabrutinib Combined With Lenalidomide and Rituximab (OR2) in the Treatment of Recurrent and Refractory CD20+ B-cell Lymphoma[NCT05014100] | Phase 2 | 55 participants (Anticipated) | Interventional | 2021-09-01 | Not yet recruiting | ||
| A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma[NCT01829568] | Phase 1 | 33 participants (Actual) | Interventional | 2013-06-21 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Duration of response is defined as the time from first evidence of a response to the first documented time of progressive disease (PD). Response and Progression were assessed using the Cheson et al. Revised Response Criteria for Malignant Lymphoma. > > A CR is defined as the disappearance of all evidence of disease. A PR is defined as ≥ 50% decrease in the sum of the products of dimensions (SPD) of up to 6 largest dominant masses; no increase in size of other nodes and regression on CT, and no increase in size of liver/spleen.Estimated using the method of Kaplan-Meier.>~> Progressive Disease (PD) is defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir." (NCT01849263)
Timeframe: Time from the date at which the patient's objective status is first noted to be a CR or PR to the earliest date progression is documented, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Treatment (Ibrutinib) | 13.9 |
"Overall response rate defined as a partial response (PR) or complete response (CR) as the objective status at any time during treatment, evaluated using the Cheson et al. Revised Response Criteria for Malignant Lymphoma. Ninety-five percent binomial confidence intervals for the true success proportion will be calculated.~A CR is defined as the disappearance of all evidence of disease. A PR is defined as ≥ 50% decrease in the sum of the products of dimensions (SPD) of up to 6 largest dominant masses; no increase in size of other nodes and regression on CT, and no increase in size of liver/spleen." (NCT01849263)
Timeframe: Up to 5 years
| Intervention | proportion of participants (Number) |
|---|---|
| Treatment (Ibrutinib) | 0.375 |
Overall Survival is defined as the time from registration to death due to any cause. Estimated using the method of Kaplan-Meier. (NCT01849263)
Timeframe: Assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Treatment (Ibrutinib) | NA |
Progression-Free Survival is defined as the time from registration to documented progression or death due to any cause, whichever occurs first. Estimated using the method of Kaplan-Meier. (NCT01849263)
Timeframe: Time from registration to progression or death due to any cause, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Treatment (Ibrutinib) | 14.0 |
Time to response is defined for all evaluable patients who have achieved a confirmed response as the time from the date of registration to the date at which the patient's objective status is first noted to be a CR or PR.The median and 95% confidence interval will be calculated using the methods of Kaplan-Meier. (NCT01849263)
Timeframe: Time from the date of registration to the date at which the patient's objective status is first noted to be a CR or PR, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Treatment (Ibrutinib) | 4.6 |
Time to subsequent treatment is defined as the time from registration to the date of initiation of subsequent treatment for lymphoma. The distribution of time to subsequent treatment will be estimated using the method of Kaplan-Meier. (NCT01849263)
Timeframe: Time from registration to the date of initiation of subsequent treatment for lymphoma, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Treatment (Ibrutinib) | 17.7 |
Time to treatment failure is defined as the time from registration to the date of treatment discontinuation due to any reason. The distribution of time to treatment failure will be estimated using the method of Kaplan-Meier. (NCT01849263)
Timeframe: Time from registration to the date of treatment discontinuation due to any reason, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Treatment (Ibrutinib) | 10.0 |
2 reviews available for adenine and Brill-Symmers Disease
| Article | Year |
|---|---|
Ibrutinib: first global approval.
Topics: Adenine; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular | 2014 |
Ibrutinib in B-cell Lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Clin | 2014 |
6 trials available for adenine and Brill-Symmers Disease
| Article | Year |
|---|---|
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.
Topics: Adenine; Antineoplastic Agents; CARD Signaling Adaptor Proteins; DNA-Binding Proteins; Exome Sequenc | 2022 |
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Frail Elderly; Humans; Lenalid | 2022 |
Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female | 2020 |
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; CARD Signaling Adaptor Protei | 2018 |
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Female; Humans; Lymphoma, Follicular; Ma | 2018 |
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Fre | 2016 |
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Fre | 2016 |
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Fre | 2016 |
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Fre | 2016 |
8 other studies available for adenine and Brill-Symmers Disease
| Article | Year |
|---|---|
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Follicular; Male; | 2020 |
Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
Topics: Adenine; Adult; Aged; Combined Modality Therapy; Disease Progression; Drug Resistance, Neoplasm; Fem | 2021 |
B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Burkitt Lymphoma; Disease Models, Animal; Dru | 2017 |
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocol | 2017 |
Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Benzamides; Disease Progression; Drug Res | 2018 |
Choosing ibrutinib wisely.
Topics: Adenine; Humans; Lymphoma, Follicular; Piperidines; Practice Patterns, Physicians'; Pyrazoles; Pyrim | 2018 |
The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proli | 2019 |
Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Pro | 2019 |